Pea, F; Viale, P; Furlanut, M I, Antimicrobial agents in elective surgery: prophylaxis or "early therapy"?, «JOURNAL OF CHEMOTHERAPY», 2003, 15, pp. 3 - 11 [articolo]
Pea F.; Russo D.; Michieli M.; Damiani D.; Fanin R.; Michelutti A.; Michelutti T.; Piccolrovazzi S.; Baccarani M.; Furlanut M., Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia, «CLINICAL PHARMACOKINETICS», 2003, 42, pp. 851 - 862 [articolo]
Pea F.; Pavan F.; Nascimben E.; Benetton C.; Scotton P.G.; Vaglia A.; Furlanut M., Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2003, 47, pp. 3104 - 3108 [articolo]
Furlanut M.; Brollo L.; Lugatti E.; Di Qual E.; Dolcet F.; Talmassons G.; Pea F., Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with respiratory tract infections, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2003, 51, pp. 101 - 106 [articolo]
Pea F.; Di Qual E.; Cusenza A.; Brollo L.; Baldassarre M.; Furlanut M., Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia, «CLINICAL PHARMACOKINETICS», 2003, 42, pp. 589 - 598 [articolo]
Pea F.; Pavan F.; Di Qual E.; Brollo L.; Nascimben E.; Baldassarre M.; Furlanut M., Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia, «JOURNAL OF CHEMOTHERAPY», 2003, 15, pp. 563 - 567 [articolo]
Viale P.; Pea F., What is the Role of Fluoroquinolones in Intensive Care?, «JOURNAL OF CHEMOTHERAPY», 2003, 15, pp. 5 - 10 [articolo]
Pea F.; Licari M.; Baldassarre M.; Furlanut M., MEGX disposition in critically-ill trauma patients: Subsequent assessments during the first week following trauma, «FUNDAMENTAL & CLINICAL PHARMACOLOGY», 2002, 16, pp. 519 - 525 [articolo]
Pea F.; Bertolissi M.; Di Silvestre A.; Poz D.; Giordano F.; Furlanut M., TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2002, 20, pp. 326 - 332 [articolo]
Scotton P.G.; Pea F.; Giobbia M.; Baraldo M.; Vaglia A.; Furlanut M., Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis, «CLINICAL INFECTIOUS DISEASES», 2001, 33, pp. e109 - e111 [articolo]
Baraldo M.; Pea F.; Poz D.; Albanese M.C.; Livi U.; Furlanut M., Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients, «TRANSPLANTATION PROCEEDINGS», 2001, 33, pp. 3151 - 3153 [articolo]
Baraldo M.; Pea F.; Poz D.; Furlanut M., Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients, «PHARMACOLOGICAL RESEARCH», 2001, 43, pp. 547 - 551 [articolo]
Brusaferro S.; Rinaldi O.; Pea F.; Faruzzo A.; Barbone F., Protocol implementation in hospital infection control practice: An Italian experience of preoperative antibiotic prophylaxis, «THE JOURNAL OF HOSPITAL INFECTION», 2001, 47, pp. 288 - 293 [articolo]
Pea F.; Brollo L.; Lugano M.; Pos L.D.; Furlanut M., Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration, «THERAPEUTIC DRUG MONITORING», 2001, 23, pp. 587 - 588 [replica/breve intervento]
Pea F.; Milaneschi R.; Baraldo M.; Lugatti E.; Talmassons G.; Furlanut M., Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring, «THERAPEUTIC DRUG MONITORING», 2000, 22, pp. 386 - 391 [articolo]
